ArticleCureus2026
Rare Ovarian Sex Cord-Stromal Tumor: Diagnostic Pitfalls and Clinical Management.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poorly differentiated Sertoli-Leydig cell tumors of the ovary are exceptionally rare and often difficult to classify, frequently requiring expert pathology review. Their clinical course can be aggressive, and therapeutic decisions are particularly complex in older patients with comorbidities. We describe a woman in her seventies who presented with advanced disease and underwent extensive cytoreductive surgery, followed by systemic chemotherapy. Despite an initial partial response, she experienced disease progression with recurrent ascites and peritoneal carcinomatosis. This case illustrates the diagnostic pitfalls, the importance of multidisciplinary evaluation, and the therapeutic dilemmas encountered when standard regimens fail. It also underscores the need to balance oncological benefit with quality-of-life considerations in elderly patients with rare ovarian malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.